
The Food and Drug Administration’s Antimicrobial Drugs Advisory Committee late yesterday voted to recommend an emergency use authorization for Merck’s investigational oral antiviral COVID-19 medicine. The drug, molnupiravir, is meant for the treatment of mild-to-moderate COVID-19 in at-risk adults.